


CINV Drugs Market to Reach USD 2.49 Bn by 2032 | Key Trends, Pipeline Therapies & Leading Players (2025–2032)

Based on region global market is segmented in to Asia Pacific, North America, Europe, Latin America, and Middle East Africa.

WILMINGTON, DE, UNITED STATES, October 20, 2025 /EINPresswire.com/ -- Global [CINV Existing and Pipeline Drugs Market](#), valued at USD 1.69 Billion in 2024, is projected to grow at a CAGR of 4.9% from 2025 to 2032, reaching approximately USD 2.49 Billion.



Global CINV Existing and Pipeline Drugs Market Overview: Innovative Antiemetic Therapies, Rising Cancer Prevalence, and Next-Generation Chemotherapy Support Driving Growth

“

“Next-generation CINV therapies, coupled with supportive oncology care adoption, are reshaping the CINV Existing and Pipeline Drugs Market landscape.”

”

Dharti Raut

Global CINV Existing and Pipeline Drugs Market is rapidly evolving, driven by rising cancer prevalence and breakthrough antiemetic therapies such as Aloxi, Akynzeo, Emend, and Rolapitant. Increasing adoption of CINV pipeline drugs across hospitals, specialty clinics, and pharmacy channels, coupled with clinical advancements by key players like GSK, Helsinn, and Heron Therapeutics, is reshaping chemotherapy-induced nausea and vomiting management, presenting lucrative opportunities, heightened competition, and a forward-looking growth trajectory in supportive oncology care.

Global CINV Existing and Pipeline Drugs Market Driven by Rising Cancer Prevalence, Technological Advancements, and Breakthrough Innovations in Global Antiemetic Therapies

Global CINV Existing and Pipeline Drugs Market is witnessing robust growth as rising cancer prevalence worldwide drives demand for chemotherapy-induced nausea and vomiting (CINV) drugs. Innovations in CINV pipeline therapies like Akynzeo, Emend, Aloxi, and Rolapitant, coupled with increasing adoption in hospitals, specialty clinics, diagnostic centers, and pharmacy channels, are fueling global market expansion.

Global CINV Existing and Pipeline Drugs Market	
By Drug Classification	Existing Drugs Pipeline Drugs
By Administration Route	Injectable Oral Transdermal
By Therapy Line	First-Line Therapy Second-Line Therapy Supportive Care
By Drug Type	Akynzeo (netupitant-palonosetron), Emend (aprepitant), Aloxi (palonosetron), Zofran Generic (ondansetron), Kytril Generic (granisetron), SUSTOL (extended release granisetron injection), Rolapitant
By End Use	Hospitals Specialty Clinics Hospital Pharmacies Drugstores
By Region	North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN (Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Viet Nam etc.) and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Colombia and Rest of South America)

Global CINV Existing and Pipeline Drugs Market Challenges: Chemotherapy-Induced Side Effects, COVID-19 Disruptions, and Antiemetic Therapy Limitations Impact Global Market Growth

Global CINV Existing and Pipeline Drugs Market faces challenges as chemotherapy-induced side effects, including nausea and vomiting, may limit patient adherence and therapy effectiveness. Furthermore, the COVID-19 impact on the CINV market disrupted drug sales and distribution, affecting revenue streams for market leaders, followers, and new entrants, highlighting critical antiemetic therapy limitations globally.

Global CINV Existing and Pipeline Drugs Market Opportunities: Innovative Pipeline Therapies and Expanding Oncology Care Drive Lucrative Growth

Global CINV Existing and Pipeline Drugs Market presents significant growth opportunities through the launch of innovative pipeline drugs, rising awareness of supportive oncology care, and expanding adoption in emerging regions such as Asia-Pacific and Latin America. These trends are driving global antiemetic drug demand and unlocking lucrative CINV pipeline drug opportunities for pharmaceutical companies worldwide.

Global CINV Existing and Pipeline Drugs Market Segmentation: Aloxi (Palonosetron) Dominance, Hospital Adoption, and Specialty Clinics Fuel Global Antiemetic Drug Demand

Global CINV Existing and Pipeline Drugs Market is segmented by drug type and end use, with Aloxi (palonosetron) leading the market due to its superior efficacy in managing chemotherapy-induced nausea and vomiting (CINV). Among end-use segments, hospitals dominate, driven by

high patient volumes, routine chemotherapy administration, and integrated hospital pharmacy access. Growing adoption in specialty clinics, hospital pharmacies, and drugstores, along with emerging pipeline therapies, is further fueling global antiemetic drug demand and accelerating CINV market growth.

Global CINV Existing and Pipeline Drugs Market Trends: Rising Cancer Prevalence, Innovative Long-Acting Pipeline Therapies, and Supportive Oncology Care Driving Global Anti-Emetic Drug Demand

Global CINV Existing and Pipeline Drugs Market is witnessing robust growth as the increasing prevalence of cancer worldwide fuels demand for chemotherapy-induced nausea and vomiting (CINV) drugs across hospitals, specialty clinics, and pharmacy channels.

A growing focus on minimizing chemotherapy side effects, including nausea and vomiting, is driving patient-centric supportive care initiatives, enhancing adherence, and boosting global demand for innovative antiemetic drugs.

Advancements in long-acting, targeted CINV pipeline therapies like Aloxi, Akynzeo, and Rolapitant are improving efficacy and patient compliance, setting new benchmarks in chemotherapy supportive care and expanding the Global CINV Existing and Pipeline Drugs Market.

Global CINV Existing and Pipeline Drugs Market 2025: GSK, Helsinn & Heron Lead Anti-Emetic Therapy Innovation, Revenue Growth, and Chemotherapy Nausea Management

GSK's oncology pipeline in the CINV Existing and Pipeline Drugs Market is advancing with multiple investigational therapies, including combination treatments enhancing antiemetic efficacy in chemotherapy-induced nausea and vomiting, with several assets expected to enter late-stage clinical trials by 2026.

Helsinn has submitted a new formulation of AKYNZEO (netupitant/palonosetron) to the European Medicines Agency (EMA) for approval in the CINV Existing and Pipeline Drugs Market, aiming to offer a more convenient dosing option for chemotherapy patients, with potential launch anticipated in early 2026.

Heron Therapeutics reported Q2 2025 net revenues of \$37.2 million in the CINV Existing and Pipeline Drugs Market, driven by the growth of CINVANTI (aprepitant) and SUSTOL (granisetron), with full-year revenue guidance of \$153–\$163 million, reflecting strong market demand and product adoption.

Global CINV Existing and Pipeline Drugs Market Regional Insights: North America and Europe Lead the CINV Existing and Pipeline Drugs Market with Innovative Anti-Emetic Therapies and Accelerated Growth

North America leads the CINV Existing and Pipeline Drugs Market, driven by high cancer prevalence, advanced oncology infrastructure, and early adoption of innovative antiemetic therapies. With key players like GSK, Helsinn, and Heron Therapeutics actively advancing their CINV pipeline drugs, the region is poised for accelerated growth in chemotherapy-induced nausea and vomiting management, shaping the future of supportive cancer care.

Europe ranks as the second largest CINV Existing and Pipeline Drugs Market, fueled by high cancer prevalence, advanced oncology infrastructure, and growing patient adoption of innovative CINV therapies. With companies like GSK, Helsinn, and Heron Therapeutics advancing pipeline antiemetics and EMA approvals accelerating market launches, the region is set to drive next-generation chemotherapy-induced nausea and vomiting treatment and expand supportive oncology care.

Maximize Market Research is a leading market research firm providing comprehensive market research solutions. For more information, visit our website:

<https://www.maximizemarketresearch.com/request-sample/38713/>

CINV Existing and Pipeline Drugs Key Players:

GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Eastman
Lonza
CHEMIDEA CHEMICALS
Teva pharmaceutical
Baxter Healthcare,
Sun Pharma,
Mylan Pharmaceuticals, Inc.,
Sandoz (Novartis AG),
Barr Laboratories, Inc.
Orchid Healthcare
Acacia Pharma
TALLC Corporation
LP Pharmaceuticals

FAQs:

What is the projected growth of the Global CINV Existing and Pipeline Drugs Market?

Ans: Global CINV Existing and Pipeline Drugs Market, valued at USD 1.69 billion in 2024, is expected to reach approximately USD 2.49 billion by 2032, growing at a CAGR of 4.9%, driven by

rising cancer prevalence and increasing adoption of innovative antiemetic therapies.

Which regions dominate the Global CINV Existing and Pipeline Drugs Market?

Ans: North America leads the CINV Existing and Pipeline Drugs Market due to high cancer prevalence, advanced oncology infrastructure, and early adoption of innovative antiemetic therapies, followed by Europe, where growing patient adoption and EMA approvals are accelerating chemotherapy-induced nausea and vomiting management.

□□□ □□□□ □□□□□□ □□ □□□ □□□□, □□□□□□□ □ □□□□□□ □□□□□□ □□□ :

<https://www.maximizemarketresearch.com/request-sample/38713/>

Who are the key players driving innovation in the Global CINV Existing and Pipeline Drugs Market?

Ans: Major companies leading the CINV Existing and Pipeline Drugs Market include GSK, Helsinn, and Heron Therapeutics, actively advancing pipeline antiemetic drugs, boosting revenue growth, and supporting next-generation chemotherapy-induced nausea and vomiting therapies globally.

Analyst Perspective:

Industry observers note that the Global CINV Existing and Pipeline Drugs Market is rapidly evolving, fueled by rising cancer prevalence and adoption of innovative antiemetic therapies. Key players like GSK, Helsinn, and Heron Therapeutics are advancing CINV pipeline drugs and driving adoption across hospitals, specialty clinics, and pharmacy channels, making the market highly competitive, attractive for strategic investments, and poised for strong growth in supportive oncology care.

Related Reports:

Viral Conjunctivitis Pipeline Drugs Market: <https://www.maximizemarketresearch.com/market-report/viral-conjunctivitis-pipeline-drugs-market/37187/>

Cancer Vaccine Drug Pipeline Market: <https://www.maximizemarketresearch.com/market-report/cancer-vaccines-drug-pipeline-market/218875/>

Pipeline Equipment Market: <https://www.maximizemarketresearch.com/market-report/pipeline-equipment-market/184572/>

Maximize Market Research is launching a subscription model for data and analysis in the

Dental Materials market:

<https://www.mmrstatistics.com/markets/461/topic/346/healthcare>

About Us :

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

Contact Us :

MAXIMIZE MARKET RESEARCH PVT. LTD.

2nd Floor, Navale IT park Phase 3,

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India.

+91 9607365656

Lumawant Godage

MAXIMIZE MARKET RESEARCH PVT. LTD.

+ +91 96073 65656

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/859719933>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.